Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Itching

imatinib mesylate has been researched along with Itching in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's3 (50.00)24.3611
2020's2 (33.33)2.80

Authors

AuthorsStudies
Cha, SH; Kim, K; Song, YK1
Attia, S; Bojanini, L; Gonzalez-Estrada, A; Heagney, H1
Allegra, A; Alonci, A; Calapai, G; Gangemi, S; Maisano, V; Mannucci, C; Musolino, C; Russo, S1
Ambrifi, M; Bottoni, U; Calvieri, S; Clerico, R; Corsetti, P; Didona, D; Paolino, G1
Kishimoto, H; Nakamura, M; Otagiri, N; Sasahara, K; Tauchi, K; Tsukada, Y; Yoshifuku, S1
Bachot, N; Bastuji-Garin, S; Berthaud, P; Giraudier, S; Revuz, J; Tulliez, M; Valeyrie, L; Wechsler, J1

Reviews

1 review(s) available for imatinib mesylate and Itching

ArticleYear
Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis.
    Acta oncologica (Stockholm, Sweden), 2023, Volume: 62, Issue:12

    Topics: Antineoplastic Agents; Dasatinib; Exanthema; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pruritus; Pyrimidines; Tyrosine Kinase Inhibitors

2023

Other Studies

5 other study(ies) available for imatinib mesylate and Itching

ArticleYear
Long induction of tolerance to imatinib.
    BMJ case reports, 2020, Dec-13, Volume: 13, Issue:12

    Topics: Antineoplastic Agents; Drug Tolerance; Exanthema; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Pruritus

2020
Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity.
    Turkish journal of haematology : official journal of Turkish Society of Haematology, 2015, Volume: 32, Issue:2

    Topics: Aged; Antineoplastic Agents; Drug Eruptions; Humans; Imatinib Mesylate; Interleukin-1 Receptor-Like 1 Protein; Interleukin-33; Interleukins; Keratinocytes; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mast Cells; Protein Kinase Inhibitors; Pruritus

2015
Skin lesions in patients treated with imatinib mesylate: a 5-year prospective study.
    Cutis, 2016, Volume: 97, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Basal Cell; Dermatitis, Seborrheic; Dermatomycoses; Drug Eruptions; Eczema; Edema; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Histiocytoma, Benign Fibrous; Humans; Imatinib Mesylate; Keratosis, Actinic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nail Diseases; Orbital Diseases; Prospective Studies; Pruritus; Psoriasis; Skin Neoplasms

2016
[Complete response achieved in a case of gastric gastrointestinal stromal tumor by administration of imatinib mesilate with concurrent relatively high-dose steroid therapy to control side effects].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:11

    Topics: Benzamides; Drug Eruptions; Drug Therapy, Combination; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Prednisolone; Pruritus; Pyrimidines; Treatment Outcome

2010
Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients.
    Journal of the American Academy of Dermatology, 2003, Volume: 48, Issue:2

    Topics: Adult; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Drug Eruptions; Edema; Exanthema; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Piperazines; Prospective Studies; Pruritus; Pyrimidines

2003